| Literature DB >> 35836105 |
Patricia C Valery1,2, Christina M Bernardes3, Kelly L Hayward4,5, Gunter Hartel3, Katelin Haynes6, Louisa G Gordon3, Katherine A Stuart5, Penny L Wright5, Amy Johnson5, Elizabeth E Powell4,5.
Abstract
BACKGROUND: Optimal management of cirrhosis is complex, and patients often lack knowledge and skills, which can affect self-management. We assessed patient knowledge about cirrhosis and examined whether knowledge was associated with clinical outcomes, healthcare service use, and healthcare costs. A cross-sectional 'knowledge survey' was conducted during 2018-2020. We assessed patient knowledge about cirrhosis and explore whether knowledge was associated with clinical outcomes, healthcare service use, and costs.Entities:
Keywords: Chronic liver disease; Healthcare cost; Hospital admissions; Patient knowledge; Survival
Mesh:
Year: 2022 PMID: 35836105 PMCID: PMC9284723 DOI: 10.1186/s12876-022-02407-6
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 2.847
Fig. 1Timeline for recruitment and collection of outcome measures
Fig. 2Frequency of participants and proportion of correct answers to the 8-item ‘knowledge survey’
Proportion of correct responses to “key knowledge” questions
| “Key knowledge” questions | N = 123 (%) |
|---|---|
| 1. Do you have cirrhosis (scarring of the liver)?* | 98 (87.5%) |
| 2. What type of liver disease do you have?** | 104 (85.2%) |
| 3. People who have cirrhosis should not drink alcohol | 115 (93.5%) |
| 4. It is safe for people with cirrhosis to take sleeping tablets and calmatives without discussing it with their liver doctor | 61 (49.6%) |
| 5. It is safe for people with cirrhosis to take natural remedies, herbs, or supplements without discussing it with their liver doctor | 59 (48.0%) |
6. For people with cirrhosis who have minor aches or pains, the following over-the-counter medications are safe to take:¥ (1) naproxen; (2) paracetamol; (3) ibuprofen; (4) aspirin; (5) diclofenac | 39 (40.6%) |
| 7. When should people with cirrhosis be screened for liver cancer?₤ (1) Never, people with cirrhosis are not at increased risk for liver cancer; (2) People with cirrhosis should be screened for liver cancer when their cirrhosis is decompensated; (3) People with cirrhosis should have an ultrasound every 6 months to screen for liver cancer; (4) I don’t know | 75 (62.0%) |
8. People with cirrhosis have an ultrasound every 6 months in order to:₤ (1) Determine liver function; (2) Look for gallstones; (3) Look for liver cancer; (4) I don’t know | 41 (33.9%) |
*Data was missing for 11 patients
**Data was missing for 1 patient
¥Examples of commonly used commercial names of medications were included in the survey provided to patients; 21 patients noted that they did not take the listed over-the-counter medications and data was missing for 6 patients
₤Data was missing for 2 patients
Factors associated with “key knowledge” about liver disease
| Poor knowledge N = 51 (%) | Good knowledge N = 72 (%) | OR (95%CI) | Adjusted-OR (95%CI)* | |
|---|---|---|---|---|
| 18–64 years | 25 (49%) | 50 (69%) | 1.00 | 1.00 |
| ≥ 65 years | 26 (51%) | 22 (31%) | 0.42 (0.20–0.89) | 0.46 (0.19–1.14) |
| Female | 20 (39%) | 22 (31%) | 1.00 | 1.00 |
| Male | 31 (61%) | 50 (69%) | 1.47 (0.69–3.12) | 1.46 (0.57–3.77) |
| Non-indigenous | 44 (86%) | 66 (92%) | 1.00 | 1.00 |
| Indigenous | 7 (14%) | 6 (8%) | 0.57 (0.18–1.82) | 0.78 (0.25–2.45) |
| Junior high school or less | 36 (71%) | 22 (31%) | 1.00 | 1.00 |
| Senior high school or more (e.g. trade qualification, university degree) | 15 (29%) | 50 (69%) | 5.45 (2.48–11.98) | 5.55 (2.40–12.84) |
| Q1 most affluent/Q2 | 16 (31%) | 37 (51%) | 1.00‡ | 1.00‡ |
| Q3 | 10 (20%) | 6 (8%) | 0.26 (0.08–0.84) | 0.24 (0.06–0.91) |
| Q4/ Q5 most disadvantage | 25 (49%) | 29 (40%) | 0.50 (0.22–1.11) | 0.47 (0.19–1.12) |
| Compensated | 39 (76%) | 48 (67%) | 1.00 | 1.00 |
| Decompensated | 12 (24%) | 24 (33%) | 1.63 (0.72–3.67) | 1.85 (0.77–4.43) |
| Diagnosed < 1 year prior | 11 (22%) | 14 (19%) | 1.00‡ | 1.00‡ |
| Diagnosed 2–3 years prior | 14 (27%) | 18 (25%) | 1.01 (0.35–2.91) | 1.46 (0.40–5.36) |
| Diagnosed > 3 years prior | 10 (20%) | 18 (25%) | 1.41 (0.47–4.29) | 2.17 (0.56–8.40) |
| Unknown | 16 (31%) | 22 (31%) | 1.08 (0.39–3.01) | 1.06 (0.33–3.38) |
Data presented as odds ratios (OR) and 95% confidence intervals (CI). The vce(robust) option was used to obtain robust standard errors for the parameter estimates to control for mild violations of underlying assumptions
*Multivariable logistic regression model included education level, socioeconomic status, age, presence of complications of cirrhosis and duration of cirrhosis
‡p value > 0.05
Fig. 3Mean SF-36 scores according to patient knowledge. Note: Missing SF-36 scores for 2 patients; *Multivariable logistic regression adjusted for education level, socioeconomic status, presence of complications of cirrhosis, and duration of cirrhosis
Adjusted incidence rate ratios and cost ratios according to knowledge score among 121 patients
| Data source: Queensland hospital admitted patient data collection | IRR (95%CI)* | Adjusted-IRR (95%CI)* | ||
|---|---|---|---|---|
| All-cause admission | 0.42 (0.35–0.49) | < 0.001 | 0.24 (0.20–0.29) | |
| Cirrhosis admission | 1.21 (0.82–1.79) | 0.338 | 0.59 (0.35–0.99) | |
| Planned one-day admission (cirrhosis admission) | 4.59 (1.79–11.73) | 3.96 (1.46–10.74) | ||
| Admitted via the emergency department (any admission) | 0.70 (0.51–0.97) | 0.51 (0.35–0.76) | ||
| Admitted via the emergency department (cirrhosis admission) | 0.90 (0.57–1.41) | 0.646 | 0.57 (0.32–1.00) | 0.050 |
Bold values indicates statistically significant (p < 0.05)
Incidence rate ratio (IRR) and cost ratio with poor knowledge as reference group
Two patients for whom we did not have hospital admission data were excluded from these analyses
*Multivariable Poisson regression model included education level, socioeconomic status, presence of complications of cirrhosis and duration of cirrhosis
**Multivariable Poisson regression model included education level, Charlson Comorbidity Index, and presence of complications of cirrhosis